Post-earnings recap
Reported
Thu, Oct 27, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Bristol Myers Squibb's earnings report indicates a positive surprise on EPS, which contributed to a slight increase in stock price. The management's focus on key therapeutic areas and R&D investments suggests a commitment to long-term growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.61 | N/A | +4.81% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed confidence in the company's strategic direction. They emphasized the importance of innovation in their product pipeline.
Management highlighted the strong performance in key therapeutic areas.
They noted ongoing investments in research and development to drive future growth.